Abstract: Embodiments of the invention provide a method of forming nickel-silicide. The method may include depositing first and second metal layers over at least one of a gate, a source, and a drain region of a field-effect-transistor (FET) through a physical vapor deposition (PVD) process, wherein the first metal layer is deposited using a first nickel target material containing platinum (Pt), and the second metal layer is deposited on top of the first metal layer using a second nickel target material containing no or less platinum than that in the first nickel target material; and annealing the first and second metal layers covering the FET to form a platinum-containing nickel-silicide layer at a top surface of the gate, source, and drain regions.

Abstract: A dispensing apparatus includes a container having an opening, and a doser coupled with the container about the container opening. The doser includes a housing forming a chamber with an interior wall, an inlet, and an outlet. The inlet is diametrically offset from the outlet, and substantially aligned with the opening of the container. The doser also includes a covering member to alternatively cover and open the inlet and the outlet. The covering member is movable about a range of positions to substantially completely cover at least one of the inlet and outlet at all positions in the range. The covering member covers no more than a portion of the chamber interior wall when the covering member completely opens the outlet.

Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.

Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO, F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.

Abstract: This disclosure relates to reagents, compositions, methods for stabilising RNA in an RNA-containing sample by contacting the sample with guanidine and a metal ion to form a stabilised RNA-containing composition in which the metal ion is present at a concentration which is no more than 20 mM, and the metal ion is derived from a metal other than from a Group 1 or Group 2 metal.

Abstract: An apparatus (100) adapted to measure Alternating Current flowing through an electricity supply distribution unit (204) having a plurality of distribution cables (202). The apparatus (100) includes a plurality of current measuring devices (102), each of the current measuring devices (102), in use, measuring current flowing through one of the distribution cables (202), at least some of the current measuring devices (102) being mounted on a rigid/semi-rigid body (104), and a device configured to store and/or transfer information representing current measured by at least one of the current measuring devices (102).

Abstract: A communication system includes first and second devices which are matched to each other. At least one of the matched devices includes an input device for capturing content; a memory for storing the content, and a renderer configured to render the content under the control of at least one processor which is configured to affect rendering of the content on the first device and/or the second device in response to at least one trigger. The least one trigger may be generated in response to detection of a user of the first device; passage of time the content has been rendered since a previous trigger; location of the user; behavioral pattern of the user; and/or traffic flow patterns between the first device and the second device.

Abstract: The present invention relates to methods for detecting a target nucleotide sequence in a sample. More particularly, the present invention relates to methods for detecting a target nucleotide sequence in a sample which utilise a nuclease-aptamer complex. The present invention also provides nuclease-binding aptamers, nuclease-aptamer complexes and linker molecules that may be used in accordance with the methods of the present invention.

Abstract: A method of producing a planar substrate having waveguide channels, which method comprises: (i) providing a tube (6) of a substrate material; (ii) depositing silica layers (110) on the inside of the tube (6), the silica layers (110) being doped with a photosensitive material; (iii) drawing the tube (6) so that the cross-sectional size of the tube (109) is reduced; (iv) before or after the reducing of the cross-sectional size of the tube (6), causing the tube (6) to collapse into a flat shape by applying a low pressure to the tube, whereby the deposited silica layers together form a photosensitive silica layer (111); (v) cutting to required lengths the tube (6) which has been collapsed and reduced in cross-sectional size; and (vi) using laser writing to define waveguide channels in the cut lengths of the tube (6) and thereby to produce the planar substrate having the waveguide channels.

Abstract: A lucent plasma crucible having a closed body for enclosing a fill material filled in a void formed within the closed body and enclosed by the closed body, the fill material being excitable by microwave energy to generate a light-emitting plasma. The crucible is dimensioned to have low order TE or TM microwave mode properties. The orders of the modes are 0, 1 or 2. Crucibles may be regular or irregular in shape. For circular cylindrical crucibles having diameter (d) in cm, length (l) in cm, and operating frequency (f) in MHZ, (d/l)2 is between 0 and 100, and (d×f)2 is between 0 and 2×109. Also 0<(d/l)2<20 and 0<(d×f)2<1.5×109 may be used.

Abstract: A lamp comprises a light source in the form of a light emitting resonator 1, a magnetron 2 and a stub tuner 3. A reflector 4 is fitted at the junction of the light source and the stub tuner, for directing the light in a generally collimated beam 5. The light emitting resonator comprises an enclosure 11 formed of inner and outer envelopes 12,13 of quartz. These are circular cylindrical tubes 14,15, with respective end plates 16,17. A tungsten wire mesh 18, of a mesh size to exhibit a ground plane to microwaves within the resonator, is sandwiched between the tubes and the end plates respectively. Each envelope, comprised of its tube and end plates is hermetic. An earth connection 18? extends from the mesh to the outside of the envelope. The length axially of the enclosure between the wire mesh sandwiched between the end plates is ?/2 for the operating microwave frequency. At one end of the enclosure, a molybdenum drive connection 19 extends to a tungsten disc 20.

Abstract: A fuel emulsion consists of diesel, water and an emulsifier composition having a hydrophile/lipophile balance value of at least 4. The emulsifier composition comprises a polymeric non-ionic surfactant having hydrophilic and hydrophobic repeating units together with at least one component selected from fatty acid esters or partial esters of polyhydric alcohols; alkoxylated fatty acid esters or partial esters of polyhydric alcohols; and alkoxylated primary alcohols. Preferred emulsifier compositions according to the invention include mixtures of the polymeric non-ionic surfactant with at least two of the components. Especially preferred compositions comprise mixtures of the polymeric non-ionic surfactant with the fatty acid (partial) esters or alkoxylated fatty acid (partial) esters. The emulsifier composition may include an emulsion coupler such as a primary alcohol, e.g. octanol.

Abstract: Methods are disclosed for forming dual damascene back-end-of-line (BEOL) interconnect structures using materials for the vias or studs which are different from those used for the line conductors, or using materials for the via liner which are different from those used for the trench liner, or having a via liner thickness different from that of the trench liner. Preferably, a thick refractory metal is used in the vias for improved mechanical strength while using only a thin refractory metal in the trenches to provide low resistance.

Abstract: Disclosed is a polymer composition derived from a bis-phenol comprising a conjugated aromatic radical, optionally comprising nitrogen. Suitable bis-phenols as well as methods for making said polymer are also disclosed. Also disclosed are electroactive layers comprising said polymer and electroactive devices comprising said layer.

Abstract: A bandpass filter comprises an air filled aluminum chamber having a lid and a cuboid resonant cavity having a central iris. At opposite end nodes of the cavity, perfect electric conductors (PECs) are provided. Threaded tuning projections opposite the PECs and in the iris are provided, whereby the pass band and the transmission characteristics of the filter in the pass band can be tuned to match the input impedance of the band pass filter and the wave guide to the output impedance of a microwave drive circuit. It is mounted on one end of the filter chamber, with an electrodeless bulb in a central cavity directed axially away from the chamber and the radiator in a further cavity set to one side of the central cavity. When the filter is driven, the wave guide resonates driving the bulb.

Abstract: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO, F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.

Abstract: This invention relates to compounds of formula (I)

Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.